HRP20190271T1 - Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije - Google Patents

Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije

Info

Publication number
HRP20190271T1
HRP20190271T1 HRP20190271TT HRP20190271T HRP20190271T1 HR P20190271 T1 HRP20190271 T1 HR P20190271T1 HR P20190271T T HRP20190271T T HR P20190271TT HR P20190271 T HRP20190271 T HR P20190271T HR P20190271 T1 HRP20190271 T1 HR P20190271T1
Authority
HR
Croatia
Prior art keywords
leukemia virus
feline leukemia
vaccine containing
envelope gene
recombinant
Prior art date
Application number
HRP20190271TT
Other languages
English (en)
Inventor
Hervé Poulet
Thierry Heidmann
Original Assignee
Merial Limited
Centre National De La Recherche Scientifique
Institut Gustave Roussy
Université Paris-Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Limited, Centre National De La Recherche Scientifique, Institut Gustave Roussy, Université Paris-Sud filed Critical Merial Limited
Publication of HRP20190271T1 publication Critical patent/HRP20190271T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HRP20190271TT 2011-07-20 2019-02-11 Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije HRP20190271T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509912P 2011-07-20 2011-07-20
EP12705199.3A EP2734230B1 (en) 2011-07-20 2012-02-02 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
PCT/US2012/023658 WO2013012446A1 (en) 2011-07-20 2012-02-02 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

Publications (1)

Publication Number Publication Date
HRP20190271T1 true HRP20190271T1 (hr) 2019-03-22

Family

ID=45722710

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190271TT HRP20190271T1 (hr) 2011-07-20 2019-02-11 Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije

Country Status (24)

Country Link
US (2) US8895027B2 (hr)
EP (1) EP2734230B1 (hr)
JP (2) JP6084970B2 (hr)
CN (1) CN103957932B (hr)
AU (2) AU2012284558B2 (hr)
BR (1) BR112014001287B1 (hr)
CA (1) CA2842055C (hr)
CY (1) CY1125328T1 (hr)
DK (1) DK2734230T3 (hr)
ES (1) ES2720150T3 (hr)
HR (1) HRP20190271T1 (hr)
HU (1) HUE043547T2 (hr)
IL (1) IL230460B (hr)
IN (1) IN2014CN00547A (hr)
LT (1) LT2734230T (hr)
MX (1) MX351642B (hr)
PL (1) PL2734230T3 (hr)
PT (1) PT2734230T (hr)
RS (1) RS58289B1 (hr)
RU (1) RU2591817C2 (hr)
SI (1) SI2734230T1 (hr)
TR (1) TR201901466T4 (hr)
WO (1) WO2013012446A1 (hr)
ZA (1) ZA201400349B (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EP3691679A2 (en) * 2017-10-06 2020-08-12 Virbac Feline vaccines conferring early protection
CN111848785B (zh) * 2020-07-10 2022-09-06 青岛博隆基因工程有限公司 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
EP0377842B1 (en) * 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
RS50325B (sr) 1999-09-25 2009-09-08 University Of Iowa Research Foundation, Imunostimulatorne nukleinske kiseline
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US7078507B2 (en) 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
DE50304603D1 (de) * 2002-09-23 2006-09-21 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
BRPI0509497B1 (pt) * 2004-03-30 2022-07-19 Institut Gustave Roussy Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais
EP1765387B1 (en) 2004-06-04 2013-01-09 Merial Limited NEEDLE-FREE ADMINISTRATION OF FeLV VACCINES
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
US8784843B2 (en) * 2005-09-16 2014-07-22 Merial Limited Stabilizers for freeze-dried vaccines
AU2008260593A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens

Also Published As

Publication number Publication date
MX351642B (es) 2017-10-23
CA2842055A1 (en) 2013-01-24
CN103957932B (zh) 2017-06-23
PL2734230T3 (pl) 2019-07-31
IL230460B (en) 2018-11-29
ZA201400349B (en) 2015-08-26
JP6240294B2 (ja) 2017-11-29
PT2734230T (pt) 2019-02-27
LT2734230T (lt) 2019-03-25
AU2012284558A1 (en) 2014-02-20
EP2734230A1 (en) 2014-05-28
BR112014001287A2 (pt) 2017-02-21
CY1125328T1 (el) 2023-03-24
BR112014001287B1 (pt) 2020-12-08
SI2734230T1 (sl) 2019-04-30
TR201901466T4 (tr) 2019-02-21
NZ620566A (en) 2016-02-26
IL230460A0 (en) 2014-03-31
AU2017204298A1 (en) 2017-07-13
CA2842055C (en) 2019-04-02
JP6084970B2 (ja) 2017-02-22
HUE043547T2 (hu) 2019-08-28
US9856295B2 (en) 2018-01-02
US20130022632A1 (en) 2013-01-24
MX2014000625A (es) 2015-06-02
JP2014528699A (ja) 2014-10-30
EP2734230B1 (en) 2018-11-21
RU2014106295A (ru) 2015-08-27
WO2013012446A1 (en) 2013-01-24
AU2012284558B2 (en) 2017-06-29
RU2591817C2 (ru) 2016-07-20
DK2734230T3 (en) 2019-01-28
US8895027B2 (en) 2014-11-25
US20150030623A1 (en) 2015-01-29
RS58289B1 (sr) 2019-03-29
IN2014CN00547A (hr) 2015-04-03
JP2017052774A (ja) 2017-03-16
CN103957932A (zh) 2014-07-30
ES2720150T3 (es) 2019-07-18

Similar Documents

Publication Publication Date Title
SG11201400432VA (en) Polypeptide vaccine
SG10201801947YA (en) Recombinant subunit dengue virus vaccine
EP2782596A4 (en) VIRAL VECTORS FOR HIGHLY EFFECTIVE TRANSGEN DELIVERY
EP2678005A4 (en) GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
EP2542703A4 (en) NEW HIV-1 ENVELOPE GLYCOPROTEIN
IL231043A (en) vaccine
IL231132A0 (en) Viral cleaning methods
HK1245104A1 (zh) Dna疫苗
ZA201309516B (en) Protein matrix vaccine compositions including polycations
ZA201209260B (en) Novel intergenic elements for enhancing gene expression
HRP20190271T1 (hr) Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije
IL239152A0 (en) Biological mixture inactivated from viruses
GB201119999D0 (en) Vaccine
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2588135A4 (en) NANO EMULSION VACCINES
EP2543387A4 (en) MUCOSAL VACCINE
EP2747779A4 (en) VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION
EP2763699A4 (en) VACCINE
EP2678043A4 (en) RECOMBINANT MUMPSVIRUS VACCINE
HK1202070A1 (en) Vaccine for tumor immunotherapy
GB201004143D0 (en) Promoter sequence for DNA and viral vectors
EP2615104A4 (en) LIPOSOMAL VACCINE AGAINST HEPATITIS C VIRUS
GB201218465D0 (en) Viral infection cofactor
GB2496849B (en) Improved DNA plasmid system
AU2011901988A0 (en) Recombinant viral vaccines